WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.

García-Lezama M, Carrillo-Ruiz JD, Moreno-Jiménez S, Roldán-Valadez E.

Open source

DOI
10.24875/gmm.m22000757
Published
2023-01-01
Container
Gac Med Mex
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.24875/gmm.m22000757,
  title = {WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.},
  author = {García-Lezama M and  Carrillo-Ruiz JD and  Moreno-Jiménez S and  Roldán-Valadez E.},
  year = {2023},
  journal = {Gac Med Mex},
  doi = {10.24875/gmm.m22000757},
  url = {https://doi.org/10.24875/gmm.m22000757}
}

RIS

TY  - JOUR
TI  - WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
AU  - García-Lezama M
AU  -  Carrillo-Ruiz JD
AU  -  Moreno-Jiménez S
AU  -  Roldán-Valadez E.
PY  - 2023
JO  - Gac Med Mex
DO  - 10.24875/gmm.m22000757
UR  - https://doi.org/10.24875/gmm.m22000757
ER  - 

APA

M, G., JD, C., S, M., & E., R. (2023). WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.. Gac Med Mex. https://doi.org/10.24875/gmm.m22000757

Source records